LEGEND BIOTECH CORP-ADR (LEGN)
US52490G1022 - ADR
We assign a fundamental rating of 4 out of 10 to LEGN. LEGN was compared to 588 industry peers in the Biotechnology industry. While LEGN seems to be doing ok healthwise, there are quite some concerns on its profitability. LEGN shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year LEGN has reported negative net income.
In the past year LEGN has reported a negative cash flow from operations.
In the past 5 years LEGN always reported negative net income.
In the past 5 years LEGN always reported negative operating cash flow.
1.2 Ratios
LEGN has a Return On Assets of -28.04%. This is in the better half of the industry: LEGN outperforms 75.00% of its industry peers.
LEGN's Return On Equity of -41.42% is fine compared to the rest of the industry. LEGN outperforms 74.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.04% | ||
| ROE | -41.42% | ||
| ROIC | N/A |
ROA(3y)-32.54%
ROA(5y)-33.85%
ROE(3y)-51.36%
ROE(5y)-53.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LEGN has a Gross Margin of 49.42%. This is amongst the best in the industry. LEGN outperforms 80.14% of its industry peers.
The Profit Margin and Operating Margin are not available for LEGN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 49.42% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LEGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
LEGN has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for LEGN has been increased compared to 5 years ago.
The debt/assets ratio for LEGN has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 9.26 indicates that LEGN is not in any danger for bankruptcy at the moment.
The Altman-Z score of LEGN (9.26) is better than 86.64% of its industry peers.
LEGN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
LEGN's Debt to Equity ratio of 0.26 is on the low side compared to the rest of the industry. LEGN is outperformed by 69.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 9.26 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
LEGN has a Current Ratio of 6.92. This indicates that LEGN is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 6.92, LEGN is doing good in the industry, outperforming 67.29% of the companies in the same industry.
A Quick Ratio of 6.83 indicates that LEGN has no problem at all paying its short term obligations.
LEGN has a better Quick ratio (6.83) than 67.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.92 | ||
| Quick Ratio | 6.83 |
3. Growth
3.1 Past
The earnings per share for LEGN have decreased by -5.12% in the last year.
Looking at the last year, LEGN shows a very strong growth in Revenue. The Revenue has grown by 143.71%.
The Revenue has been growing by 42.17% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-5.12%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q70.5%
Revenue 1Y (TTM)143.71%
Revenue growth 3Y56.08%
Revenue growth 5Y42.17%
Revenue growth Q2Q-32.08%
3.2 Future
LEGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.81% yearly.
Based on estimates for the next years, LEGN will show a very strong growth in Revenue. The Revenue will grow by 56.21% on average per year.
EPS Next Y49.07%
EPS Next 2Y34.17%
EPS Next 3Y30.9%
EPS Next 5Y25.81%
Revenue Next Year92.01%
Revenue Next 2Y87.12%
Revenue Next 3Y74.64%
Revenue Next 5Y56.21%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LEGN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LEGN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LEGN's earnings are expected to grow with 30.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.17%
EPS Next 3Y30.9%
5. Dividend
5.1 Amount
No dividends for LEGN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LEGEND BIOTECH CORP-ADR
NASDAQ:LEGN (4/26/2024, 7:00:54 PM)
After market: 45.3 0 (0%)45.3
+0.88 (+1.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap8.24B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.04% | ||
| ROE | -41.42% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 49.42% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.92 | ||
| Quick Ratio | 6.83 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-5.12%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y49.07%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)143.71%
Revenue growth 3Y56.08%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y